Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE), a Canadian cannabis company, reported Tuesday its financial results for the third quarter, revealing revenue of CA$12.2 million ($8.97 million), down by 8.8% from CA$13.4 million in the same quarter last year.
"I am proud to announce the strategic initiatives we've undertaken to drive cost reduction, enhance profitability, and strengthen our balance sheet over the past year," stated George Scorsis, CEO and chair of Entourage. "Through the consolidation of operations and the integration of advanced automation, we have not only achieved heightened efficiency but also experienced improvement in our overall financial performance. In the face of challenges within the Canadian cannabis sector, our Q3 performance reinforces our strategy, marking a pivotal moment in the ongoing narrative of Entourage’s success."
Vaani Maharaj, CFO of Entourage, commented, “Throughout the year, we’ve been proactive in our approach, implementing strategic measures such as the realignment of our product portfolio. By consistently evaluating performance, market demand, and product pricing, we are demonstrating agility in the industry. Although this quarter saw a revenue decline in adult-use the measures we have implemented are instrumental in fortifying our financial resilience and positioning us for sustained growth.”
Related Links
Photo: Courtesy of Washarapol D BinYo Jundang via Pexels